Andina Acquisition Corp. III
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANDA research report →
Range $6 – $6
Price Chart
About the company
Andina Acquisition Corp. III operates as a blank check company, specifically formed to pursue a business combination. Its primary objective is to engage in a transaction such as a merger, share swap, asset purchase, stock acquisition, financial restructuring, or corporate reorganization with one or more other entities.
- CEO
- Julio A. Torres Garca
- IPO
- 2019
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on ANDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $335.92M
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 3.17
- EV/EBITDA
- -294.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,140,000
- Net Income
- $0-100.0%
- EPS
- $0.00-100.0%
- OCF Growth
- +36.3%
- FCF Growth
- +36.3%
- 52W High
- $14.00
- 52W Low
- $8.70
- 50D MA
- $10.18
- 200D MA
- $10.54
- Beta
- 0.00
- Avg Volume
- 30.34K
No earnings-call transcripts are available for ANDA yet.
- Free Float
- 51.3%
- Shares Outstanding
- 18.26M
- Float Shares
- 9.36M
of shares held by institutions
14 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cowen Inc. | 32.10K | ▲ 32.10K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 20, 21 | Casey Ted | other | 1,491,314 |
| Jul 20, 21 | Casey Ted | other | 1,491,314 |
| Jul 20, 21 | Casey Ted | other | 1,478,524 |
| Jul 20, 21 | Casey Ted | other | 1,478,524 |
| Jul 20, 21 | Casey Ted | other | 128,306 |
| Jul 20, 21 | Casey Ted | other | 101,301 |
| Jul 20, 21 | Casey Ted | other | 128,306 |
| Jul 20, 21 | Alt Jaxie S. | other | 121,078 |
| Jul 20, 21 | Alt Jaxie S. | other | 121,078 |
| Jul 20, 21 | Alt Jaxie S. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANDA coverage
Recent articles, reports, and earnings notes.
No research on ANDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANDA report →FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
globenewswire.com · Aug 7
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
gurufocus.com · Jun 3
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
globenewswire.com · Feb 17
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
globenewswire.com · Dec 2
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
globenewswire.com · Oct 3
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
businesswire.com · Jun 5
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
globenewswire.com · May 28
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
globenewswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.